There are currently 619 clinical trials in Austin, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Dell Childrens Medical Center of Central Texas, Pfizer Investigational Site and University of Texas at Austin. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
NCT06293053
Recruiting
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: * Screening period: 2 to 4 weeks. * Treatment period: 24 weeks. * Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods). The total number of planned study visits for each participant will be 6.
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
03/04/2025
Locations: Dell Children's Medical Center- Site Number : 8400007, Austin, Texas
Conditions: Prurigo Nodularis
Register for Updates
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988
Recruiting
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/04/2025
Locations: Austin Research Center for Retina, Austin, Texas +1 locations
Conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Register for Updates
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene
NCT06188702
Recruiting
This is a first-in-human Phase 1, multicenter, open-label dose escalation study of S095035 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: NEXT Oncology, Austin, Texas
Conditions: MTAP-deleted Solid Tumors
Register for Updates
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
NCT04617522
Recruiting
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: NEXT Austin, Austin, Texas
Conditions: Advanced or Metastatic Solid Tumor, Liver Failure
Register for Updates
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391
Recruiting
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
03/03/2025
Locations: Velocity Clinical Research - Austin, Austin, Texas +2 locations
Conditions: Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes
Register for Updates
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281
Recruiting
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/02/2025
Locations: Austin Heart, Austin, Texas
Conditions: Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Register for Updates
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
02/28/2025
Locations: Dell Children's Medical Center of Central Texas, Austin, Texas
Conditions: H3 K27M, Glioma
Register for Updates
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Austin Epilepsy Care Center (AECC), Austin, Texas
Conditions: Focal Onset Seizures
Register for Updates
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
NCT06511752
Recruiting
The current study aims to examine the benefits of an education/support group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners. The current study utilizes pre-, post-treatment, and follow-up assessments to measure effects of a psychoeducational support group and an implementation/communication skills training phase on measures of psychosocial function, communicative effectiveness and speech/language function. Analysis of study-speci... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: University of Texas at Austin, Austin, Texas
Conditions: Alzheimer Disease, Dementia, Primary Progressive Aphasia, Aphasia, Progressive Aphasia, Progressive Aphasia in Alzheimer's Disease
Register for Updates
Amplatzer Amulet LAAO Vs. NOAC
NCT04226547
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Texas Cardiac Arrhythmia, Austin, Texas
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
TIDE Project: Biomarker Discovery for Chronic Tinnitus Diagnosis
NCT06520865
Recruiting
Research in clinical neuroscience is founded on the conviction that a better understanding of tinnitus related changes of brain function will improve our ability to diagnose and treat tinnitus. Although considerable advances have been made in understanding the mechanisms of tinnitus, the clinical management of tinnitus remains largely based on a 'trial and error' approach. The identification and validation of a biomarker for tinnitus is thought to be the crucial step in the development of a pers... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/24/2025
Locations: University of Texas, Austin, Texas
Conditions: Tinnitus
Register for Updates
A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults
NCT06851871
Recruiting
The purpose of this study is to evaluate the bioequivalence between immediate release tablets and minitablets of Deucravacitinib (BMS-986165), and the effect of food and pH on the drug levels of the minitablets in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/24/2025
Locations: Local Institution - 0002, Austin, Texas +1 locations
Conditions: Healthy Participants
Register for Updates